Business Context and Reporting Period
The supplied filing is Aileron Therapeutics, Inc.’s Form 10-K for the fiscal year ended December 31, 2017, not Rein Therapeutics, Inc. The company was a clinical-stage biopharmaceutical developer focused on stapled peptides. Its lead candidate, ALRN-6924, was being evaluated in Phase 1 and Phase 2a oncology trials for solid tumors, peripheral T-cell lymphoma, AML and MDS.
The filing also provides unaudited fourth-quarter 2017 data. Aileron completed its initial public offering in July 2017, raising $50.0 million in net proceeds, and all outstanding preferred stock converted into common stock.
Financial Metrics
| Metric | 2017 | 2016 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No change |
| Research and development expense | $14.2 million | $10.3 million | +$4.0 million |
| General and administrative expense | $8.8 million | $7.9 million | +$0.9 million |
| Total operating expenses | $23.0 million | $18.2 million | +$4.8 million |
| Loss from operations | $(23.0) million | $(18.2) million | Loss increased |
| Net loss | $(22.6) million | $(18.1) million | Loss increased $4.5 million |
| Net loss attributable to common stockholders | $(22.6) million | $(18.2) million | Loss increased $4.4 million |
| Net loss per share | $(3.04) | $(42.35) | Improved due primarily to increased share count |
| Cash, cash equivalents and investments | $50.8 million | $20.7 million | +$30.0 million |
| Working capital | $46.9 million | $17.0 million | +$29.9 million |
| Stockholders’ equity | $47.8 million | $(111.8) million | Improved after IPO and preferred conversion |
Operating cash flow was negative $20.5 million, compared with negative $15.0 million in 2016. Investing activities used $38.9 million, primarily reflecting purchases of short-term investments. Financing activities provided $50.6 million, principally from the IPO. The filing does not disclose material debt; reported liabilities were $4.9 million at year-end.
There was no meaningful revenue base against which to calculate operating or net margins. Fourth-quarter 2017 net loss was $6.9 million, with research and development expense of $4.3 million and general and administrative expense of $2.7 million.
Material Changes Versus the Prior Comparable Period
- Research and development spending increased 39%, driven mainly by higher ALRN-6924 clinical activity, contract manufacturing costs, AML/MDS trials and additional personnel.
- General and administrative expense increased 11%; 2016 included a $1.5 million write-off of postponed offering costs, while 2017 included higher public-company and personnel costs.
- Cash resources increased substantially following the IPO, although operating cash burn also rose.
- Preferred stock with a carrying value of $130.4 million converted into 10.5 million common shares at the IPO, eliminating redeemable preferred stock from the balance sheet.
- Stock-based compensation increased to $1.7 million from $0.7 million.
Guidance, Outlook, Risks and Unusual Items
Management expected the year-end 2017 cash, cash equivalents and investments to fund operating and capital requirements into the second half of 2019. The audited financial statement note states that funding was expected to be sufficient for at least the next twelve months from April 2, 2018, but emphasizes the need for substantial additional financing. No committed external funding source existed.
- Management expected additional interim PTCL and AML/MDS data in the second half of 2018 and potentially FDA discussions regarding an expedited PTCL pathway as early as the fourth quarter of 2018.
- The company could initiate Phase 2a AML/MDS studies as early as the fourth quarter of 2018, subject to clinical results and timing.
- ALRN-6924 had not received marketing approval, and the company had no commercial products or product revenue.
- If approval is pursued for WT p53-selected patients, a companion diagnostic may be required, creating additional development and regulatory risk.
- The active pharmaceutical ingredient was sourced from a single contract manufacturer, with no redundant supply arrangement in place.
- Clinical results were preliminary and based on small, uncontrolled studies. PTCL response assessments differed under IWG 2014 and modified Cheson 2007 criteria, increasing interpretive and regulatory risk.
- The company disclosed a prior dispute with Harvard regarding diligence milestones under a key license agreement. Harvard had not pursued termination as of the filing, but loss of the license could materially impair ALRN-6924 commercialization.
- The company had no material legal proceedings and no off-balance-sheet arrangements. Its Cambridge lease expired in May 2018, with plans to move to a new facility.
Investor Verification Items
- Confirm the issuer identity: the supplied text identifies Aileron Therapeutics, Inc., while the request metadata identifies Rein Therapeutics, Inc.
- Verify current cash runway, subsequent financings and whether the anticipated second-half 2019 funding horizon was achieved.
- Review later clinical data for ALRN-6924, particularly response durability, safety, PTCL assessment criteria and progression into pivotal trials.
- Confirm the status of required companion-diagnostic development and regulatory discussions with the FDA.
- Review subsequent changes to the Harvard/DFCI license, manufacturing supply arrangements and milestone obligations.
- Assess dilution from future equity offerings, stock options and other equity-linked instruments; 2.1 million options were outstanding at December 31, 2017.